KCS Wealth Advisory Has $248,000 Position in Becton Dickinson and Co (NYSE:BDX)

KCS Wealth Advisory lowered its position in Becton Dickinson and Co (NYSE:BDX) by 9.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 911 shares of the medical instruments supplier’s stock after selling 96 shares during the quarter. KCS Wealth Advisory’s holdings in Becton Dickinson and were worth $248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in BDX. Allworth Financial LP raised its position in shares of Becton Dickinson and by 386.4% in the third quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 85 shares during the period. Northwest Investment Counselors LLC bought a new position in shares of Becton Dickinson and in the third quarter valued at about $27,000. Liberty Wealth Management LLC raised its position in shares of Becton Dickinson and by 293.1% in the third quarter. Liberty Wealth Management LLC now owns 114 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 85 shares during the period. CX Institutional bought a new position in shares of Becton Dickinson and in the third quarter valued at about $31,000. Finally, North Star Investment Management Corp. bought a new position in shares of Becton Dickinson and in the third quarter valued at about $45,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

NYSE:BDX opened at $277.30 on Thursday. Becton Dickinson and Co has a 52 week low of $221.47 and a 52 week high of $279.62. The firm has a market cap of $74.64 billion, a price-to-earnings ratio of 23.74, a P/E/G ratio of 1.97 and a beta of 1.07. The firm’s 50-day simple moving average is $267.92 and its 200 day simple moving average is $256.09. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, topping analysts’ consensus estimates of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The business had revenue of $4.58 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period last year, the firm earned $2.93 earnings per share. Becton Dickinson and’s revenue for the quarter was up 4.1% compared to the same quarter last year. Sell-side analysts anticipate that Becton Dickinson and Co will post 12.57 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Tuesday, December 10th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 1.14%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date was Monday, December 9th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.05%.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 19,675 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $275.15, for a total value of $5,413,576.25. Following the transaction, the chief executive officer now directly owns 227,647 shares of the company’s stock, valued at approximately $62,637,072.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Vincent A. Forlenza sold 13,860 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $275.19, for a total transaction of $3,814,133.40. Following the completion of the transaction, the chief executive officer now directly owns 227,647 shares in the company, valued at $62,646,177.93. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 91,231 shares of company stock worth $24,787,690. 0.12% of the stock is owned by insiders.

Several brokerages have recently weighed in on BDX. JPMorgan Chase & Co. increased their price objective on shares of Becton Dickinson and from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. KeyCorp dropped their price objective on shares of Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. Morgan Stanley increased their price objective on shares of Becton Dickinson and from $261.00 to $287.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Stifel Nicolaus increased their price objective on shares of Becton Dickinson and from $275.00 to $295.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Finally, Barclays lowered shares of Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective on the stock. in a research report on Wednesday, January 8th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $277.70.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: What are the benefits of a portfolio tracker?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.